MDRX / Veradigm Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 4) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name

8-A12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 4) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer

Veradigm Amends and Extends Stockholder Rights Plan

EX-99.1 Exhibit 99.1 Veradigm Amends and Extends Stockholder Rights Plan Chicago – August 20, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the “Board”) has approved an amendment to extend the Company’s existing Stockholder Rights Plan for an additional six months (the “Rights Plan”). The Rights Plan,

AMENDMENT NO. 5 TO STOCKHOLDER RIGHTS AGREEMENT

EX-4.6 Exhibit 4.6 AMENDMENT NO. 5 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 5 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of August 20, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 VERADIGM INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb

VERADIGM inc. EMPLOYMENT AGREEMENT

Exh. 10.1 VERADIGM inc. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made this 15th day of August, 2025 (the “Signing Date”) and effective as of September 2, 2025 (the “Effective Date”), by and between Veradigm Inc., a corporation organized and existing under the laws of the State of Delaware (“Company”), and Donald Trigg (“Executive”). RECITALS WHEREAS, commencing on the E

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Veradigm Appoints Don Trigg as Chief Executive Officer Former apree health CEO, Cerner President will Lead Next Phase of Company Growth

Exh. 99.1 Veradigm Appoints Don Trigg as Chief Executive Officer Former apree health CEO, Cerner President will Lead Next Phase of Company Growth CHICAGO – August 18, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that its Board of Directors has appointed Don Trigg, an industry leader with over two decades of healthcare technology

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T

AMENDMENT STOCKHOLDER AGREEMENT

EX-10.1 Exhibit 10.1 AMENDMENT TO STOCKHOLDER AGREEMENT This AMENDMENT (this “Amendment”), dated as of July 24, 2025, is by and among Veradigm Inc. (the “Company”), Charles Myers (“Myers”) and Jessica Myers (together with Myers, the “Myers Parties”). Each of the Company, on the one hand, and Myers or the Myers Parties, on the other hand, is referred to herein as a “party”, and all of the Company a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 VERADIGM INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number

THIRD AMENDMENT TO VERADIGM INC. (A DELAWARE CORPORATION), AS AMENDED AND RESTATED ON AUGUST 18, 2015

EX-3.1 Exhibit 3.1 THIRD AMENDMENT TO BY-LAWS OF VERADIGM INC. (A DELAWARE CORPORATION), AS AMENDED AND RESTATED ON AUGUST 18, 2015 This Third Amendment (this “Amendment”) to the By-Laws, as amended and restated on August 18, 2015 and as further amended on January 1, 2023 and December 7, 2023 (the “By-Laws”), of Veradigm Inc., a Delaware corporation f/k/a Allscripts Healthcare Solutions, Inc. (the

FORM 8-K Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number

Veradigm Provides 2025 Financial & Business Update

Exhibit 99.1 Veradigm Provides 2025 Financial & Business Update CHICAGO – June 23, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, is providing an update on commercial activity and estimated financial performance for the first quarter of 2025 compared to the prior year, details about its recent financing, and reaffirmation of its outlook for the 20

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number

CREDIT AGREEMENT VERADIGM INC., VERADIGM LLC, as Borrowers, the Lenders Party Hereto, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Administrative Agent and Collateral Agent Dated as of June 18, 2025

EX-10.1 Exhibit 10.1 Execution Version CREDIT AGREEMENT among VERADIGM INC., and VERADIGM LLC, as Borrowers, the Lenders Party Hereto, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Administrative Agent and Collateral Agent Dated as of June 18, 2025 THE LOANS ISSUED PURSUANT TO THIS AGREEMENT WERE ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR PURPOSES OF SECTION 1271 ET SEQ. OF THE UNITED STATES INTERNAL REVE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 VERADIGM INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number

VERADIGM INC. AMENDED AND RESTATED 2024 STOCK INCENTIVE PLAN I. INTRODUCTION

Exhibit 10.1 VERADIGM INC. AMENDED AND RESTATED 2024 STOCK INCENTIVE PLAN I. INTRODUCTION 1.1. Purposes. The purposes of the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success,

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CE

NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 VERADIGM INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

SEPARATION AGREEMENT

EX-10.1 Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is effective as of the 22nd day of April, 2025 (the “Effective Date”), by and between Tom Langan (“Executive”) and Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc., a corporation organized and existing under the laws of the State of Delaware (“Company”). Terms used in this Agreement but not

April 22, 2025

EX-10.2 Exhibit 10.2 April 22, 2025 Leland Westerfield Re: Renewal Agreement Dear Lee: This letter confirms our mutual agreement to extend the term of your employment as Interim Chief Financial Officer and Interim Chief Accounting Officer of Veradigm Inc. (the “Company”) under the Letter Agreement, dated December 7, 2023, between you and the Company (the “Letter Agreement”) through December 31, 20

GRANT THORNTON LLP

EX-16.1 EXHIBIT 16.1 GRANT THORNTON LLP April 17, 2025 4140 ParkLake Ave., Suite 130 Raleigh, NC 27612 D +1 919 881 2700 U.S. Securities and Exchange Commission F +1 919 881 2795 Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Veradigm Inc. File No. 000-32085 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Veradigm Inc. dated April 14, 2025, and agree with the sta

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (C

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Veradigm Files Fiscal 2022 Form 10-K and Restated Financial Statements

Exhibit 99.2 Veradigm Files Fiscal 2022 Form 10-K and Restated Financial Statements CHICAGO – March 18, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that it filed its comprehensive Annual Report on Form 10-K for the year ended December 31, 2022, which also contains certain restated financial statements for periods in fiscal year

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Veradigm Provides Updates on Fiscal 2023 and 2024 and an Outlook for Fiscal 2025

Exhibit 99.1 Veradigm Provides Updates on Fiscal 2023 and 2024 and an Outlook for Fiscal 2025 CHICAGO – March 18, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, provided updates on financial information for fiscal 2023 and 2024 and an outlook for fiscal 2025. “We remain confident in Veradigm’s business model and our value proposition,” said Tom La

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.9 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Veradigm Inc. (“Veradigm,” “we,” “us” or “our”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share (“Common Stock”), and the rights (each, a “Right”

Veradigm Inc. Dodd-Frank Policy on Recoupment of Incentive Compensation

Exhibit 97.1 VERADIGM INC. DODD-FRANK POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Board of Directors (the “Board”) of Veradigm Inc. (the “Company”) has adopted this Dodd-Frank Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-32085 VERADIGM INC. (Exact name of registrant as specified in its

Employment Agreement, effective as of February 13, 2018. by and between Allscripts Healthcare Solutions, Inc. and Thomas Langan

Exhibit 10.52 allscripts healthcare solutions, inc. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made this 13th day of February, 2018 (the “Signing Date” and “Effective Date”), by and between Allscripts Healthcare Solutions, Inc., a corporation organized and existing under the laws of the State of Delaware (“Company”), and Tom Langan (“Executive”). RECITALS WHEREAS, commenc

Form of Restricted Stock Unit Award Agreement (Executive Chairman) (2024)

Exhibit 10.43 VERADIGM INC. Restricted Stock Unit Award Agreement (Executive Chairman) THIS AGREEMENT is made as of %%OPTION DATE, ‘Month DD, YYYY”%-% (the “Grant Date”), by and between Veradigm Inc., a Delaware corporation (“Company”), and MERGEFIELD FirstName %%FIRSTNAME%-% MERGEFIELD LastName %%LASTNAME%-% ( MERGEFIELD LastName %%LASTNAME%-%). WHEREAS, MERGEFIELD LastName %%LASTNAME%-% is expec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 3) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name

8-A12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 3) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer

Amendment No. 4 to Stockholder Rights Agreement, dated as of March 18, 2025, by and between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent

Exhibit 4.5 AMENDMENT NO. 4 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 4 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of March 18, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that certain

Offer Letter Agreement, effective as of December 7, 2023, by and between Veradigm Inc. and P. Gregory Garrison

Exhibit 10.55 December 6, 2023 P. Gregory Garrison Dear Greg: It is my pleasure to offer you the position of Executive Chairman (“Executive Chairman”) of the Board of Directors (the “Board”) of Veradigm Inc. (the “Company”), pursuant to the terms of this letter agreement (the “Offer Letter”). The terms and conditions of your employment with the Company will be as follows and shall, subject to your

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

VERADIGM INC.

EXHIBIT 21.1 VERADIGM INC. SUBSIDIARIES Subsidiary Jurisdiction or State of Organization Allscripts Holdings, LLC Delaware Allscripts Holdings 2, LLC Delaware Coniston Exchange, LLC Delaware Allscripts Healthcare US, LP Delaware Veradigm LLC North Carolina Allscripts Software, LLC Delaware California Healthcare Medical Billing, LLC California Allscripts Analytics, LLC Delaware Allscripts Next, LLC

Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to succeed Greg Garrison as Chairman

Exhibit 99.1 Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to succeed Greg Garrison as Chairman CHICAGO – March 18, 2025 – Veradigm Inc. (OTCMKTS: MDRX) (“Veradigm” or the “Company”), a leading provider of healthcare data and technology solutions, announced today its Board of Dire

Registration Rights Agreement, dated as of March 18, 2025, by and between Veradigm Inc. and Stonehill Capital Management LLC

EX-10.1 Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 18, 2025, is entered into by and between Veradigm Inc., a Delaware corporation (the “Company”), and Stonehill Capital Management LLC (the “Investor”). WHEREAS: The Company’s board of directors (the “Board”) desires to appoint Jonathan Sacks, who serves as a Partner of Investo

Form of Restricted Stock Unit Award Agreement (Directors) (2024)

Exhibit 10.42 VERADIGM INC. Restricted Stock Unit Award Agreement (Directors) THIS AGREEMENT is made as of %%OPTION DATE, ‘Month DD, YYYY”%-% (the “Grant Date”), by and between Veradigm Inc., a Delaware corporation (“Company”), and MERGEFIELD FirstName %%FIRSTNAME%-% MERGEFIELD LastName %%LASTNAME%-% ( MERGEFIELD LastName %%LASTNAME%-%). WHEREAS, MERGEFIELD LastName %%LASTNAME%-% is expected to pe

Confidentiality Agreement, dated as of March 18, 2025, by and among Veradigm Inc., Jonathan Sacks and Stonehill Capital Management LLC

Exhibit 10.2 CONFIDENTIALITY AGREEMENT This confidentiality agreement (this “Confidentiality Agreement”) is made and entered into as of March 18, 2025, by and among Veradigm Inc., a Delaware corporation (the “Company”), on the one hand, and (i) Stonehill Capital Management LLC, a Delaware limited liability company (collectively with its Affiliates (as defined below), “Stonehill”) and (ii) Jonathan

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108 (Check one):  ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D  ☐ Form N-CE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-32085 CUSIP NUMBER 01988P108 (Check one):  ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name

8-A12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer

Veradigm Announces Board Expansion and Changes Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors

Exhibit 99.1 Veradigm Announces Board Expansion and Changes Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors CHICAGO – February 20, 2025 – Veradigm® (OTCMKTS: MDRX) (“Veradigm” or the “Company”), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the “Agreement”) with K

Veradigm Amends and Extends Stockholder Rights Plan

Exhibit 99.1 Veradigm Amends and Extends Stockholder Rights Plan Chicago – February 20, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the “Board”) has approved an amendment to extend the Company’s existing Stockholder Rights Plan (the “Rights Plan”). The Rights Plan, adopted on February 26, 2024, was d

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Amendment No. 3 to Stockholder Rights Agreement, dated as of February 20, 2025, by and between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (incorporated by reference to Exhibit 4.4 to the Company’s Form 8-K, filed on February 20, 2025)

Exhibit 4.4 AMENDMENT NO. 3 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 3 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of February 20, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that cert

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-32085 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Cooperation Agreement, dated as of February 20, 2025, by and between Veradigm Inc. and Kent Lake PR LLC

Exhibit 4.1 COOPERATION AGREEMENT This cooperation agreement (this “Agreement”) is made and entered into as of February 20, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), on the one hand, and Kent Lake PR LLC, a Puerto Rico limited liability company (“Kent Lake”), on the other hand. The Company and Kent Lake are each herein referred to as a “party” and collectively, th

Amendment No. 2 to Stockholder Rights Agreement, dated as of February 13, 2025, by and between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (incorporated by reference to Exhibit 4.3 to the Company’s Form 8-K, filed on February 20, 2025)

Exhibit 4.3 AMENDMENT NO. 2 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 2 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of February 13, 2025, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that cert

Veradigm Announces the Resignation of Board Director Beth Altman Due to Health Reasons

Exhibit 99.1 Veradigm Announces the Resignation of Board Director Beth Altman Due to Health Reasons CHICAGO – January 30, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that on January 28, 2025 Beth Altman stepped down from the Company’s Board of Directors (“Board”) due to health reasons. Her decision to resign was not the result o

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March

Exhibit 99.2 Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March CHICAGO – January 30, 2025 – Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directo

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Letter Agreement, dated December 31, 2024, between the Company and Leland Westerfield

Exhibit 10.1 December 31, 2024 Leland Westerfield Re: Renewal Agreement Dear Lee: This letter confirms our mutual agreement to extend the term of your employment as Interim Chief Financial Officer and Interim Chief Accounting Officer of Veradigm Inc. (the “Company”) under the Letter Agreement, dated December 7, 2023, between you and the Company (the “Letter Agreement”) through June 30, 2025 (such

MDRX / Veradigm Inc. / Madison Avenue Partners, LP Passive Investment

SC 13G/A 1 veradigm13ga1-11142024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Veradigm Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01988P108 (CUSIP Numbe

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

EX-99.A 2 d894473dex99a.htm EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments th

MDRX / Veradigm Inc. / Silver Point Capital L.P. - SC 13G Passive Investment

SC 13G 1 d894473dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Veradigm Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

MDRX / Veradigm Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Veradigm Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Veradigm Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under th

MDRX / Veradigm Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Veradigm Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 VERADIGM INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number

Stockholder Agreement, dated as of July 26, 2024, by and among Veradigm Inc., Charles Myers and Jessica Myers

EX-10.1 Exhibit 10.1 PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K, THIS EXHIBIT OMITS CERTAIN INFORMATION, IDENTIFIED BY [***], THAT IS NOT MATERIAL AND THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STOCKHOLDER AGREEMENT This STOCKHOLDER AGREEMENT, dated as of July 26, 2024 (this “Agreement”), is by and among Veradigm Inc. (the “Company”), Charles Myers (“Myers”) and Jessica Myers (t

MDRX / Veradigm Inc. / Madison Avenue Partners, LP Passive Investment

SC 13G 1 veradigm13g-06042024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Veradigm Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01988P108 (CUSIP Number) Ma

Veradigm Announces Leadership Updates Tom Langan appointed as interim CEO Interim CFO Lee Westerfield extends term with Company

Exhibit 99.2 Veradigm Announces Leadership Updates Tom Langan appointed as interim CEO Interim CFO Lee Westerfield extends term with Company CHICAGO – May 28, 2024 – Veradigm Inc. (OTCMKTS: MDRX, the “Company”), a leading provider of healthcare data and technology solutions, today announced that, on June 7, 2024, Tom Langan, the Company’s President and Chief Commercial Officer (CCO), will assume t

Form of Agreement for the Payment of Benefits Following Termination of Employment

EX-10.6 Exhibit 10.6 VERADIGM INC. AGREEMENT FOR THE PAYMENT OF BENEFITS FOLLOWING TERMINATION OF EMPLOYMENT This AGREEMENT, dated as of May 21, 2024 (the “Effective Date”), between VERADIGM INC., a Delaware corporation (the “Company”), and [] (the “Executive”), W I T N E S S E T H: WHEREAS, the Executive is employed by the Company in the position of [] of the Company; and WHEREAS, the Company and

Letter Agreement, dated May 27, 2024, between the Company and Leland Westerfield

EX-10.1 Exhibit 10.1 CONFIDENTIAL DRAFT May 27, 2024 Leland Westerfield Re: Renewal Agreement Dear Lee: This letter confirms our mutual agreement to extend the term of your employment as Interim Chief Financial Officer and Interim Chief Accounting Officer of Veradigm Inc. (the “Company”) under the Letter Agreement, dated December 7, 2023, between you and the Company (the “Letter Agreement”) throug

Form of Performance Unit Award Agreement

EX-10.4 Exhibit 10.4 Name: [] Number of Shares Subject to the Stock [] Date of Grant: [] VERADIGM INC. Restricted Stock Unit Award Agreement Performance-Based Vesting – Relative TSR THIS AGREEMENT is made as of the Grant Date, by and between Veradigm Inc., a Delaware corporation (“Company”), and [] (the participant). WHEREAS, in recognition of your services to the Company, the Company considers it

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 VERADIGM INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Veradigm Inc. 2024 Stock Incentive Plan

EX-10.5 Exhibit 10.5 VERADIGM INC. 2024 STOCK INCENTIVE PLAN I. INTRODUCTION 1.1. Purposes. The purposes of the Veradigm Inc. 2024 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, (ii) to advance the interests of

Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance

EX-99.1 Exhibit 99.1 Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance CHICAGO – May 28, 2024 – Veradigm Inc. (OTCMKTS: MDRX, the “Company”), a leading provider of healthcare data and technology solutions, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of the evaluation process, Veradigm will explore pot

Form of Restricted Stock Unit Award Agreement

Exhibit 10.2 Name: [] Number of Shares Subject to the Stock [] Date of Grant: [] VERADIGM INC. Restricted Stock Unit Award Agreement THIS AGREEMENT is made as of the Grant Date, by and between Veradigm Inc., a Delaware corporation (“Company”), and [] (the participant). WHEREAS, in recognition of your services to the Company, the Company considers it desirable and in its best interests that the par

Form of Restricted Stock Unit Award Agreement (Westerfield)

Exhibit 10.3 Name: Leland Westerfield Number of Shares Subject to the Stock [     ] Date of Grant: [     ] VERADIGM INC. Restricted Stock Unit Award Agreement THIS AGREEMENT is made as of the Grant Date, by and between Veradigm Inc., a Delaware corporation (“Company”), and the participant (the participant). WHEREAS, in recognition of your services to the Company, the Company considers it desirable

MDRX / Veradigm Inc. / Kent Lake Capital LLC - SC 13D Activist Investment

SC 13D 1 n4288x1-sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Veradigm Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01988P108 (CUSIP N

Joint Filing Agreement, dated May 16, 2024.

EX-99.1 2 exh99-1.htm JOINT FILING AGREEMENT, DATED MAY 16, 2024 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, par value $0.01 per

Amendment No. 1 to Stockholder Rights Agreement, dated as of May 10, 2024, by and between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K, filed on May 13, 2024)

Exhibit 4.2 AMENDMENT NO. 1 TO STOCKHOLDER RIGHTS AGREEMENT This Amendment No. 1 to Stockholder Rights Agreement (this “Amendment”) is made and entered into as of May 10, 2024, by and between Veradigm Inc., a Delaware corporation (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, as rights agent (the “Rights Agent”), and amends that certain S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name

8-A12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ 

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 VERADIGM INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 VERADIGM INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Third Amendment, dated as of March 29, 2024, to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022, among Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.), Veradigm LLC (f/k/a Allscripts Healthcare, LLC), the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.1 EXECUTION VERSION THIRD AMENDMENT THIRD AMENDMENT, dated as of March 29, 2024 (this “Amendment”), to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022 (as amended by the First Amendment, dated as of November 20, 2023, as amended by the Second Amendment, dated as of January 31, 2024, and as further amended, supplemented or otherwise modified from time to time

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Veradigm Announces Initial Financial Guidance for Fiscal 2024

Exhibit 99.1 Veradigm Announces Initial Financial Guidance for Fiscal 2024 CHICAGO – March 13, 2024 – Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Co

Disclaimer & Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, expected finan

Barclays Healthcare Investor Conference Veradigm Miami, Florida | March 13, 2024 Exhibit 99.

MDRX / Veradigm Inc. / Kent Lake Capital LLC - VERADIGM 13G Passive Investment

SC 13G 1 mdrx13gv1.htm VERADIGM 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Veradigm Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 01988P108 (CUSIP Number) March 1, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

MDRX / Veradigm Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Veradigm Inc Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: February 29, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

MDRX / Veradigm Inc. / Newtyn Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VERADIGM INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 01988P108 (CUSIP Number) February 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

MDRX / Veradigm Inc. / STONEHILL CAPITAL MANAGEMENT LLC - SC 13G Passive Investment

SC 13G 1 d759701dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Veradigm Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 01988P108 (CUSIP Number) February 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriat

AGREEMENT OF JOINTING FILING

EX-99.1 2 d759701dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT OF JOINTING FILING Stonehill Capital Management LLC, Stonehill Master Fund Ltd., Stonehill Institutional Partners, L.P, John Motulsky, Peter Sisitsky, Michael Thoyer, Jonathan Sacks, Michael Stern and Samir Arora hereby agree that the Statement on Schedule 13G to which this agreement is attached as an exhibit as well as all future amendments

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one):  ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D  ☐ Form N-CE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one):  ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Veradigm Receives Expected Delisting Notice from Nasdaq Continues to Work Diligently Towards Regaining Compliance

Exhibit 99.1 Veradigm Receives Expected Delisting Notice from Nasdaq Continues to Work Diligently Towards Regaining Compliance CHICAGO – February 28, 2024 – Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, announced today that, as expected, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 VERADIGM INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Veradigm Provides Update on its Financial Restatement Process Expects Not to File Required Financial Statements by Nasdaq’s February 27, 2024 Deadline Working Diligently to File Required Financial Statements and Restore Listing Adopts Limited Duratio

Exhibit 99.2 Veradigm Provides Update on its Financial Restatement Process Expects Not to File Required Financial Statements by Nasdaq’s February 27, 2024 Deadline Working Diligently to File Required Financial Statements and Restore Listing Adopts Limited Duration Stockholder Rights Plan CHICAGO – February 27, 2024 – Veradigm Inc. (NASDAQ: MDRX) (the “Company”), a leading provider of healthcare da

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as sp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 VERADIGM INC. (Exact name of registrant as specified in its charter) Delaware 36-4392754 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 222 Merch

Stockholder Rights Agreement, dated as of February 26, 2024, by and between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto) (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-A, filed on February 27, 2024)

Exhibit 4.1 STOCKHOLDER RIGHTS AGREEMENT Veradigm Inc. and Broadridge Corporate Issuer Solutions, LLC, as Rights Agent Dated as of February 26, 2024 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 9 Section 3. Issuance of Rights Certificates 10 Section 4. Form of Rights Certificates 12 Section 5. Countersignature and Registration 13 Section 6. Transfe

Certificate of Designation of the Series A Junior Participating Preferred Stock of the Company, dated February 26, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-A, filed on February 27, 2024)

Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF VERADIGM INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that the following resolution was duly adopted by the board of directors of Veradigm Inc., a Delaware corporation (the “Corporation”), on February 26, 2024: RESOLVED, that pursuant t

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 VERADIGM INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Certificate of Designation of the Series A Junior Participating Preferred Stock of the Company, dated February 26, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on February 27, 2024)

Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF VERADIGM INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that the following resolution was duly adopted by the board of directors of Veradigm Inc., a Delaware corporation (the “Corporation”), on February 26, 2024: RESOLVED, that pursuant t

Agreement and Plan of Merger, dated as of February 21, 2024, by and among Veradigm Inc., Veradigm Merger Sub, Inc., Cascade Bio, Inc., certain equityholders of Cascade Bio, Inc. and Fortis Advisors LLC

EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among VERADIGM INC., VERADIGM MERGER SUB, INC., CASCADE BIO, INC., EACH OF THE DESIGNATED EQUITYHOLDERS, EACH OF THE OTHER MANAGEMENT EQUITYHOLDERS, and FORTIS ADVISORS LLC, as Equityholder Representative FEBRUARY 21, 2024 TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INTERPRETATIONS 2 1.1 Definitions 2 1.2 Additional Defined Terms 22 1.3 Interp

Stockholder Rights Agreement, dated as of February 26, 2024, by and between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto) (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on February 27, 2024)

Exhibit 4.1 STOCKHOLDER RIGHTS AGREEMENT Veradigm Inc. and Broadridge Corporate Issuer Solutions, LLC, as Rights Agent Dated as of February 26, 2024 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 9 Section 3. Issuance of Rights Certificates 10 Section 4. Form of Rights Certificates 12 Section 5. Countersignature and Registration 13 Section 6. Transfe

Veradigm to Acquire ScienceIO Veradigm to Leverage ScienceIO’s Leading Healthcare Artificial Intelligence (AI) Platform on the Company’s Large-Scale, High-Quality Data Set to Build Advanced, Private Language Models for Healthcare Expected to Provide

Exhibit 99.1 Veradigm to Acquire ScienceIO Veradigm to Leverage ScienceIO’s Leading Healthcare Artificial Intelligence (AI) Platform on the Company’s Large-Scale, High-Quality Data Set to Build Advanced, Private Language Models for Healthcare Expected to Provide Highly Differentiated and More Advanced Products to Veradigm Customers Acquisition Will Help Accelerate Platform Improvements Across the

MDRX / Veradigm Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02199-veradigminc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Veradigm Inc Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule

MDRX / Veradigm Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Veradigm Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

MDRX / Veradigm Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Veradigm Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

First Supplemental Indenture, dated as of February 5, 2024, by and between Veradigm Inc. and U.S. Bank Trust Company, National Association, as successor in interest to U.S. Bank National Association, as trustee

Exhibit 4.1 Execution Copy VERADIGM INC. (formerly known as Allscripts Healthcare Solutions, Inc.) AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of February 5, 2024 TO THE INDENTURE Dated as of December 9, 2019 0.875% Convertible Senior Notes due 2027 FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of February 5, 2024, be

Capped call transaction amendment, dated as of February 5, 2024, by and between Wells Fargo Bank, National Association and Veradigm Inc.

Exhibit 10.2 Execution Version Wells Fargo Bank, National Association 30 Hudson Yards New York, NY 10001-2170 DATE: February 5, 2024 TO: Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.) 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 ATTENTION: General Counsel TELEPHONE: (312) 386-6751 EMAIL: [email protected] FROM: Wells Fargo Bank, National Association SUBJECT: Amend

Capped call transaction amendment, dated as of February 5, 2024, by and between Deutsche Bank AG, London Branch and Veradigm Inc.

Exhibit 10.4 Execution Version Deutsche Bank Deutsche Bank AG, London Branch Winchester house 1 Great Winchester St, London EC2N 2DB Telephone: 44 20 7545 8000 c/o Deutsche Bank Securities Inc. 60 Wall Street New York, NY 10005 Telephone: (212) 250-2500 DATE: February 5, 2024 TO: Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.) 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 AT

Capped call transaction amendment, dated as of February 5, 2024, by and between Bank of America, N.A. and Veradigm Inc.

Exhibit 10.3 Execution Version Bank of America, N.A. One Bryant Park New York, NY 10036 DATE: February 5, 2024 TO: Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.) 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 ATTENTION: General Counsel TELEPHONE: (312) 386-6751 EMAIL: [email protected] FROM: Bank of America, N.A. SUBJECT: Amendment No. 1 To Capped Call Transactions

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

Capped call transaction amendment, dated as of February 5, 2024, by and between JPMorgan Chase Bank, National Association, New York Branch and Veradigm Inc.

Exhibit 10.1 Execution Version JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 DATE: February 5, 2024 TO: Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.) 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 ATTENTION: General Counsel TELEPHONE: (312) 386-6751 EMAIL: [email protected] FROM: JPMorgan Chase Bank, National Associ

Second Amendment, dated as of January 31, 2024, to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022, among Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.), Veradigm LLC (f/k/a Allscripts Healthcare, LLC), the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.1 EXECUTION VERSION SECOND AMENDMENT SECOND AMENDMENT, dated as of January 31, 2024 (this “Amendment”), to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022 (as amended by the First Amendment, dated as of November 20, 2023, and as further amended, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), among VERAD

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

New Veradigm Leadership Provides Outlook on Business and Strategy, and Refreshed Financial Estimates for Fiscal 2023

Exh. 99.1 New Veradigm Leadership Provides Outlook on Business and Strategy, and Refreshed Financial Estimates for Fiscal 2023 CHICAGO – January 10, 2024 – The new leadership team at Veradigm Inc. (NASDAQ: MDRX),a leading provider of healthcare data and technology solutions, has provided refreshed estimated, unaudited ranges of financial information for fiscal 2023. Dr. Shih-Yin Ho, Interim CEO, a

JP Morgan Healthcare Conference Building for the Future January 10, 2024 Exh. 99.2

JP Morgan Healthcare Conference Building for the Future January 10, 2024 Exh. 99.2 Disclaimer & Forward-Looking Statements The estimated financial results contained in this presentation are preliminary, and final results for fiscal year 2023 may change. These preliminary results are based upon our estimates and are subject to completion of our financial closing procedures. In addition, these preli

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2024 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

Veradigm Inc. Announces that Nasdaq Hearings Panel has Granted its Continued Listing, Pending Return to Compliance with Nasdaq Filing Requirements

Exhibit 99.1 Veradigm Inc. Announces that Nasdaq Hearings Panel has Granted its Continued Listing, Pending Return to Compliance with Nasdaq Filing Requirements CHICAGO – December 13, 2023 – Veradigm Inc. (NASDAQ: MDRX (the “Company”)) announced today that it received a decision from the Nasdaq Hearings Panel (the “Panel”) granting its request for continued listing on the Nasdaq Capital Market, sub

Offer Letter Agreement, effective as of December 7, 2023, between Veradigm Inc. and Shih-Yin Ho

Exhibit 10.1 December 6, 2023 Dr. Shih-Yin Ho Dear Yin: It is my pleasure to offer you the position of Interim Chief Executive Officer (“Interim CEO”) of Veradigm Inc. (the “Company”), pursuant to the terms of this letter agreement (the “Offer Letter”). The terms and conditions of your employment with the Company will be as follows and shall, subject to your satisfaction of the “Conditions to Empl

Consulting Agreement, effective as of December 7, 2023, between Veradigm Inc. and Leah S. Jones

EX-10.6 Exhibit 10.6 CONSULTING AGREEMENT Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc.) (“Company”) and Leah Jones (“Contractor”) hereby enter into this Consulting Agreement (“Agreement”) effective as of the 7th day of December, 2023 (“Effective Date”) for good and valuable consideration and mutually agree as follows: 1. Consulting Period. Subject to the terms of this Agr

Veradigm Inc. Announces Leadership Transition Greg Garrison Named Executive Chairman; Dr. Shih-Yin Ho Appointed Interim CEO; Lee Westerfield Appointed Interim CFO

EX-99.1 Exhibit 99.1 Veradigm Inc. Announces Leadership Transition Greg Garrison Named Executive Chairman; Dr. Shih-Yin Ho Appointed Interim CEO; Lee Westerfield Appointed Interim CFO CHICAGO – DECEMBER 8, 2023 – Veradigm Inc. (Nasdaq: MDRX) announced today that the Company’s Board of Directors appointed current Chairman, Greg Garrison, as Executive Chairman, and current director, Dr. Shih-Yin (“Y

Second Amendment to By-Laws of Veradigm Inc.

EX-3.1 Exhibit 3.1 SECOND AMENDMENT TO BY-LAWS OF VERADIGM INC. (A DELAWARE CORPORATION), AS AMENDED AND RESTATED ON AUGUST 18, 2015 This Second Amendment (this “Amendment”) to the By-Laws, as amended and restated on August 18, 2015 and as further amended on January 1, 2023 (the “By-Laws”), of Veradigm Inc., a Delaware corporation f/k/a Allscripts Healthcare Solutions, Inc. (the “Corporation”), is

Consulting Agreement, effective as of December 7, 2023, between Veradigm Inc. and Leland Westerfield, sole and managing member of Wilcox Capital LLC

EX-10.3 Exhibit 10.3 CONSULTING AGREEMENT Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc.) (“Company”) and Leland Westerfield, sole and managing member of Wilcox Capital LLC (“Contractor”) hereby enter into this Consulting Agreement (“Agreement”) effective as of December 7, 2023 (“Effective Date”) for good and valuable consideration and mutually agree as follows: 1. Consulti

Separation Agreement, dated as of December 6, 2023, between Veradigm Inc. and Leah S. Jones

Exhibit 10.5 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is effective as of the 6th day of December, 2023 (the “Effective Date”), by and between Leah Jones (“Executive”) and Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc. (“Allscripts”)), a corporation organized and existing under the laws of the State of Delaware (“Company”). WHEREAS, Company and Execu

Separation Agreement, dated as of December 6, 2023, between Veradigm Inc. and Richard J. Poulton

Exhibit 10.4 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is effective as of the 6th day of December, 2023 (the “Effective Date”), by and between Richard Poulton (“Executive”) and Veradigm Inc. (formerly known as Allscripts Healthcare Solutions, Inc. (“Allscripts”)), a corporation organized and existing under the laws of the State of Delaware (“Company”). Terms used in this Ag

Offer Letter Agreement, effective as of December 7, 2023, between Veradigm Inc. and Leland Westerfield

EX-10.2 Exhibit 10.2 December 7, 2023 Leland Westerfield [*****] Dear Lee: It is my pleasure to offer you the position of Interim Chief Financial Officer (“Interim CFO”) of Veradigm Inc. (the “Company”), pursuant to the terms of this letter agreement (the “Offer Letter”). The terms and conditions of your employment with the Company will be as follows and shall, subject to your satisfaction of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 VERADIGM INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

First Amendment, dated as of November 20, 2023, to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022, among Veradigm Inc. (f/k/a Allscripts Healthcare Solutions, Inc.), Veradigm LLC (f/k/a Allscripts Healthcare, LLC), the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.1 Exhibit A EXECUTION VERSION FIRST AMENDMENT FIRST AMENDMENT, dated as of November 20, 2023 (this “Amendment”), to the Third Amended and Restated Credit Agreement, dated as of April 29, 2022 (as amended, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”), among VERADIGM INC. (under its former name ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Exhibit 99.1 Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing CHICAGO – November 17, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr

Veradigm Inc. Announces Receipt of Nasdaq Stay Extension

Exh. 99.1 Veradigm Inc. Announces Receipt of Nasdaq Stay Extension CHICAGO – October 9, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that, on October 6, 2023, it received a notice from Nasdaq indicating that the temporary stay of delisting of the Company’s common stock has been extended pending a hearing before the Nasdaq Hearings Panel (the “Panel”) on November 16, 2023, and the issuance o

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 06, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal

Exh. 99.1 Veradigm Inc. Announces Receipt of Nasdaq Delisting Notice and Intent to Appeal CHICAGO – September 22, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that, on September 20, 2023 and as anticipated in its September 18 release, it received a notice from Nasdaq indicating that the Company’s shares would be delisted due to noncompliance with Nasdaq Listing Rule 5250(c)(1), because the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File N

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File N

Veradigm Inc. Provides Audit Update and Updates Financial Guidance for 2023

Exh. 99.1 Veradigm Inc. Provides Audit Update and Updates Financial Guidance for 2023 CHICAGO – September 18, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that the work effort to conclude on its previously disclosed accounting and internal control errors has taken longer than previously expected, and more time is needed to complete its audit procedures. As such, today the Company will not b

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Exh. 99.1 Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing CHICAGO – August 18, 2023 – Veradigm Inc. (NASDAQ: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the “

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit

Veradigm Inc. Receives Approval from Nasdaq of Plan to Regain Listing Compliance

Exh. 99.1 Veradigm Inc. Receives Approval from Nasdaq of Plan to Regain Listing Compliance CHICAGO – JUNE 13, 2023 –Veradigm Inc. (Nasdaq: MDRX) announced today that Nasdaq has accepted the Company’s plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) and granted the Company an exception until September 18, 2023 to file its Annual Report on Form 10-K for the year ended December 31, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Exh. 99.1 Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing CHICAGO – MAY 19, 2023 –Veradigm Inc. (Nasdaq: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results

Exh. 99.1 Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing, Provides Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results CHICAGO – MARCH 22, 2023 –Veradigm Inc. (Nasdaq: MDRX) announced today an update on the status of its year-end audit procedures for 2022. As the Company disclosed on February 28, 2023, due to an expansion of year-end audit procedures, the

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Veradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results

EX-99.1 Exhibit 99.1 Veradigm Inc. Update on 4th Quarter and Full Fiscal Year 2022 Reporting of Results CHICAGO – FEBRUARY 28, 2023 – Veradigm Inc. (NASDAQ: MDRX), announced today that in conjunction with its year-end audit procedures it has detected certain internal control failures related to revenue recognition that have occurred over the prior six quarters, resulting in a mis-statement to repo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-35547 CUSIP NUMBER 01988P108 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Veradigm Announces Two New Appointments to its Board Pharmaceutical executive Susan Rodriguez and digital health/pharma services entrepreneur Dr. Shih-Yin Ho join Board of Directors

Exh. 99.1 Veradigm Announces Two New Appointments to its Board Pharmaceutical executive Susan Rodriguez and digital health/pharma services entrepreneur Dr. Shih-Yin Ho join Board of Directors CHICAGO – FEBRUARY 22, 2023 – Susan Rodriguez and Shih-Yin Ho, MD have been named to the Board of Directors of Veradigm Inc. (NASDAQ: MDRX). With their combined experience in the pharmaceutical industry, digi

MDRX / Allscripts Healthcare Solutions Inc / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Allscripts Healthcare Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

MDRX / Allscripts Healthcare Solutions Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Allscripts Healthcare Solutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Sc

VeradigmJ.P. Morgan Healthcare Conference January 11, 2023 Exh. 99.2

Veradigm J.P. Morgan Healthcare Conference January 11, 2023 Exh. 99.2 Veradigm | Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our 2023 outlook. These forward-looking statements are based on the current beliefs and expectations of Veradigm management, only

Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023

Exh. 99.1 Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023 CHICAGO – JANUARY 11, 2023 – Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase p

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 01, 2023 VERADIGM INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation) (Commission File Num

Certificate of Amendment of Fifth Amended and Restated Certificate of Incorporation of Allscripts Healthcare Solutions, Inc.

Exh. 3.1 CERTIFICATE OF AMENDMENT OF FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: FIRST: That the Board of Directors of the Corporation, at a meeting duly held, adopted a resolution proposing and

Allscripts Announces Corporate Name Change to Veradigm Inc.

Exh. 99.1 Allscripts Announces Corporate Name Change to Veradigm Inc. CHICAGO ? JANUARY 3, 2023 ? Allscripts Healthcare Solutions, Inc. announced today that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand during 2022, and Allscripts will now formally be known as Veradigm. The US healthcare ec

First Amendment to By-Laws of Allscripts Healthcare Solutions, Inc.

Exh. 3.2 FIRST AMENDMENT TO BY-LAWS OF ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (a Delaware corporation), as amended and restated on August 18, 2015 This First Amendment (this ?Amendment?) to the By-Laws, as amended and restated on August 18, 2015 (the ?By-Laws?), of Allscripts Healthcare Solutions, Inc., a Delaware corporation (the ?Corporation?), is made as of January 1, 2023 in accordance with Art

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name o

Form of Restricted Stock Unit Award Agreement for CEO Awards Program

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Restricted Stock Unit Award Agreement CEO Awards Program ? One Year Vesting THIS AGREEMENT is made as of ?Date? (the ?Grant Date?), by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (?Company?), and ?FirstName? ?LastName? (?LastName?). WHEREAS, ?LastName? is expected to perform valuable services for the Company and the Company consid

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 3, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporati

Allscripts announces third quarter of 2022 results

Exhibit 99.1 Allscripts announces third quarter of 2022 results Third quarter consolidated revenue of $152 million Third quarter consolidated operating profit up over 30% year-over-year Generated $42 million of cash flow from continuing operations in the quarter CHICAGO-(BUSINESS WIRE)-November 3, 2022-Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial result

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorpora

Allscripts| Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current beliefs and expectation

Investor Day September 28, 2022 Allscripts/Veradigm Exhibit 99.1 Allscripts| Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subj

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Reg

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 4, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation

Allscripts Announces Second Quarter of 2022 Results

Exhibit 99.1 Allscripts Announces Second Quarter of 2022 Results Second quarter bookings of $107 million and $172 million year-to-date, up 10% from the first half of 2021 Generated $42 million of cash flow from continuing operations in the quarter CHICAGO-(BUSINESS WIRE)-August 4, 2022-Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three a

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 mdrx-def14a20220621.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

Allscripts announces first quarter of 2022 results

Exhibit 99.1 Allscripts announces first quarter of 2022 results • First quarter GAAP diluted EPS of $0.17; non-GAAP diluted EPS of $0.13 • Closed the sale of Hospital & Large Physician Practices business segment to Constellation Software • Generated $35 million of cash flow from continuing operations in the quarter CHICAGO – May 5, 2022 – Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allsc

Second Amendment, effective as of May 6, 2022, to the Employment Agreement, dated as of December 19, 2012, by and between Allscripts Healthcare Solutions, Inc. and Paul M. Black

Exhibit 10.1 SECOND AMENDMENT (“AMENDMENT”) TO THE EMPLOYMENT AGREEMENT BETWEEN ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. AND PAUL M. BLACK WHEREAS, Allscripts Healthcare Solutions, Inc. (the “Company”) and Paul M. Black (“Executive”) previously entered into an Employment Agreement dated December 19, 2012, and an Amendment No. 1 to Employment Agreement dated October 1, 2015 (collectively, the “Agreeme

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 02, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation)

Financial Tables Follow ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 2021

Exhibit 99.2 Allscripts Healthcare Solutions, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) Overview On May 2, 2022, Allscripts Healthcare Solutions, Inc., a Delaware corporation (the “Company”), Allscripts Healthcare, LLC, a North Carolina limited liability company (“Allscripts Healthcare”), Allscripts Software, LLC, a Delaware limited

Third Amended and Restated Credit Agreement, dated as of April 29, 2022, among Allscripts Healthcare Solutions, Inc., Allscripts Healthcare, LLC, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent

Exhibit 10.1 Execution Version THIRD AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 29, 2022 among ALLSCRIPTS HEALTHCARE SOLUTIONS, INC., as Borrower, ALLSCRIPTS HEALTHCARE, LLC as Co-Borrower, The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent U.S. BANK NATIONAL ASSOCIATION, BANK OF AMERICA, N.A., BMO HARRIS BANK N.A., ROYAL BANK OF CANADA and PNC BANK, NATIONAL A

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation

Allscripts Closes Sale of Hospital and Large Physician Practices Business to Constellation Software

Exhibit 99.1 Allscripts Closes Sale of Hospital and Large Physician Practices Business to Constellation Software CHICAGO ? May 2, 2022 ? Allscripts Healthcare Solutions, Inc. (Nasdaq:MDRX) today announced that it has completed the sale of the net assets of the Allscripts Hospital and Large Physician Practices business segment to Constellation Software Inc. (TSX:CSU), through its wholly-owned subsi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of regis

Purchase Agreement, dated as of March 2, 2022, by and among Allscripts Healthcare Solutions, Inc., a Delaware corporation, Allscripts Healthcare, LLC, a North Carolina limited liability company, Allscripts Software, LLC, a Delaware limited liability company, PF2 EIS LLC, a Delaware limited liability company, Allscripts IHC, LLC, a Delaware limited liability company, Allscripts Healthcare US, LP, a Delaware limited partnership, Harris Dawn Holdings Inc., a Delaware corporation, and, solely for purposes of Article VI and Section 12.18 thereof, Constellation Software Inc., an Ontario corporation.

EXHIBIT 2.1 Execution Version Purchase Agreement by and among Allscripts Healthcare Solutions, Inc., Allscripts Healthcare, LLC, Allscripts Software, LLC, PF2 EIS LLC, Allscripts IHC, LLC, Allscripts Healthcare US, LP, HARRIS DAWN HOLDINGS INC. and CONSTELLATION SOFTWARE INC. Dated as of March 2, 2022 Table of Contents Article I DEFINITIONS 2 Article II The transaction 2 2.1 Purchase and Sale 2 2.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation)

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 2, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation)

Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including the preliminary financial information included in this presentati

Allscripts Healthcare Solutions Investor Update, March 3, 2022 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including the preliminary financial information included in this presentation, are based on the current beliefs and expectations of Allscripts manage

Allscripts to Sell the Net Assets of Its Hospitals & Large Physician Practices Business Segment to Constellation Software

Exhibit 99.1 Allscripts to Sell the Net Assets of Its Hospitals & Large Physician Practices Business Segment to Constellation Software CHICAGO ? March 2, 2022 ? Allscripts Healthcare Solutions (NASDAQ: MDRX) (?Allscripts?) announced today that it has reached an agreement with Constellation Software Inc. (TSX:CSU), through its wholly-owned subsidiary N. Harris Computer Corporation (?Harris?), to se

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation)

Form of Performance-Based Restricted Stock Unit Award Agreement

Exhibit 10.29 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Performance-Based Restricted Stock Unit Award Agreement Performance-Based Vesting THIS AGREEMENT is made as of [], [] (the ?Grant Date?), by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (?Company?), and ?FirstName? ?LastName? (the ?Participant?). WHEREAS, the Participant is expected to perform valuable services for th

Form of Performance-Based Restricted Stock Unit Award Agreement (TSR) (Relative) (2021)

Exhibit 10.28 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Performance-Based Restricted Stock Unit Award Agreement Performance-Based Vesting ? Relative TSR THIS AGREEMENT is made as of [] (the ?Grant Date?), by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (?Company?), and ?FirstName? ?LastName? (the ?Participant?). WHEREAS, the Participant is expected to perform valuable serv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of registr

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

EXHIBIT 21.1 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. SUBSIDIARIES Subsidiary Jurisdiction or State of Organization Allscripts Holdings, LLC Delaware Allscripts Holdings 2, LLC Delaware Coniston Exchange, LLC Delaware Allscripts Healthcare US, LP Delaware Allscripts Healthcare, LLC North Carolina Allscripts Managed Services, LLC Delaware Allscripts Software, LLC Delaware California Healthcare Medical

Form of Restricted Stock Unit Award Agreement (Directors) (2019)

Exhibit 10.20 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Restricted Stock Unit Award Agreement (Directors) THIS AGREEMENT is made as of (the ?Grant Date?), by and between Allscripts Healthcare Solutions, Inc., a Delaware corporation (?Company?), and {First Name} {Last Name} (?{Last Name}?). WHEREAS, {Last Name} is expected to perform valuable services for the Company as a member of the Board of Directo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporat

Allscripts Announces Fourth Quarter and Fiscal Year 2021 Results

Exhibit 99.1 Allscripts Announces Fourth Quarter and Fiscal Year 2021 Results Fourth quarter GAAP diluted EPS of $0.68; non-GAAP diluted EPS of $0.79 Fourth quarter bookings of $219 million up 21% from the fourth quarter of 2020 Generated $66 million of cash flow from continuing operations in the quarter CHICAGO-(BUSINESS WIRE)-February 24, 2022-Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX)

MDRX / Allscripts Healthcare Solutions Inc / SHAPIRO CAPITAL MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

MDRX / Allscripts Healthcare Solutions Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Allscripts Healthcare Solutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Sc

MDRX / Allscripts Healthcare Solutions Inc / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Allscripts Healthcare Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2022 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporati

Twelve Months Ended December 31,

Exh. 99.1 Allscripts Announces Preliminary Fourth Quarter and Fiscal Year 2021 Results and New Share Repurchase Program CHICAGO ? January 24, 2022 ? Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) today announced preliminary financial results for the three and twelve months ended December 31, 2021. Revenue for the fourth quarter of 2021 is expected to be between $390 million and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 4, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporati

Allscripts Announces Third Quarter 2021 Results

Exhibit 99.1 Allscripts Announces Third Quarter 2021 Results Third quarter GAAP diluted EPS of $0.12; non-GAAP diluted EPS of $0.27, up 145% year-over-year Generated $57 million of cash flow from continuing operations and $35 million of free cash flow in the third quarter Increasing 2021 outlook for Adjusted EBITDA and free cash flow CHICAGO-(BUSINESS WIRE)-November 4, 2021-Allscripts Healthcare S

First Amendment to Employment Agreement between Allscripts Healthcare Solutions, Inc. and Lisa Khorey

Exhibit 10.1 FIRST AMENDMENT (?AMENDMENT?) TO THE EMPLOYMENT AGREEMENT BETWEEN ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. AND LISA KHOREY WHEREAS, Allscripts Healthcare Solutions, Inc. (the ?Company?) and Lisa Khorey (?Executive?) previously entered into an Employment Agreement dated November 1, 2016 (the ?Agreement?); and WHEREAS, the Company and Executive previously entered into the Agreement and now

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Reg

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 5, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation

Allscripts Announces Second Quarter 2021 Results

Exhibit 99.1 Allscripts Announces Second Quarter 2021 Results Second quarter GAAP diluted EPS of $0.15; non-GAAP diluted EPS of $0.23, up 35% year-over-year Generated $69 million of cash flow from continuing operations and $51 million of free cash flow in the second quarter Increasing 2021 outlook for Adjusted EBITDA and free cash flow CHICAGO-(BUSINESS WIRE)-August 5, 2021-Allscripts Healthcare S

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation)

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation)

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Re

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 29, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporation

Allscripts Announces First Quarter 2021 Results

EX-99.1 2 a52420285ex991.htm EXHIBIT 99.1 Exhibit 99.1 Allscripts Announces First Quarter 2021 Results First quarter GAAP EPS of $0.06; non-GAAP diluted EPS of $0.19 First quarter bookings of $194 million up 6% from the first quarter of 2020 Generated $56 million of cash flow from continuing operations and $35 million of free cash flow in the first quarter CHICAGO-(BUSINESS WIRE)-April 29, 2021-Al

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10 )* Allscripts Healthcare Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) March 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Allscripts Healthcare Solutions, Inc. (?Allscripts,? ?we,? ?us? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock. The following summary of the material terms of our capital stock is not meant to be

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact name of registr

Accelerated Share Repurchase Master Confirmation dated November 30, 2020

Exhibit 10.6 EXECUTED VERSION November 30, 2020 From: JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY, 10179 To: Allscripts Healthcare Solutions, Inc. 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 Attention: Richard J. Poulton Telephone No.:312.506.1216 Email:[email protected]; [email protected] Re: Master Confirmation?Uncol

Accelerated Share Repurchase Master Confirmation dated November 30, 2020

Exhibit 10.5 EXECUTED VERSION November 30, 2020 From: Wells Fargo Bank, National Association 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] To: Allscripts Healthcare Solutions, Inc. 222 Merchandise Mart Plaza, Suite 2024 Chicago, IL 60654 Attention: Richard J. Poulton Telephone No.:312.506.1216 Email:[email protected]; legal.notices@allscri

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

EXHIBIT 21.1 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. SUBSIDIARIES Subsidiary Jurisdiction or State of Organization Allscripts Holdings, LLC Delaware Allscripts Holdings 2, LLC Delaware Coniston Exchange, LLC Delaware Allscripts Healthcare US, LP Delaware Allscripts Healthcare, LLC North Carolina Allscripts Managed Services, LLC Delaware Allscripts Software, LLC Delaware California Healthcare Medical

Allscripts Announces Fourth Quarter 2020 Results and Outlook For 2021

Exhibit 99.1 Allscripts Announces Fourth Quarter 2020 Results and Outlook For 2021 Fourth quarter GAAP EPS of $4.82; 71% year-over-year growth in non-GAAP diluted EPS to $0.29 Closed sales of EPSi and CarePort Health and recognized a combined pre-tax gain of $1.2 billion Repurchased $280 million of stock in the quarter and ended the quarter in a net cash position CHICAGO-(BUSINESS WIRE)-February 2

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 25, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Allscripts Healthcare Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Allscripts Healthcare Solutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 01988P108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Sch

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9 )* Allscripts Healthcare Solutions, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 01988P108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

Regulation FD Disclosure, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2021 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporati

Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including the preliminary financial information included in this presentati

Allscripts Healthcare Solutions J.P. Morgan Virtual Healthcare Conference| January 2021 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including the preliminary financial information included in this presentation, are based on the current beliefs and expectat

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2020 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporat

Allscripts closes previously announced sale of CarePort Health business

Exhibit 99.1 Allscripts closes previously announced sale of CarePort Health business CHICAGO – January 4, 2021 – On December 31, 2020, Allscripts (NASDAQ: MDRX) closed the previously announced sale of its CarePort Health business to WellSky® Corporation for $1.35 billion. CarePort solutions assist hundreds of hospitals and thousands of post-acute care providers to efficiently coordinate and transi

Financial Tables Follow ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2020

Exhibit 99.2 Allscripts Healthcare Solutions, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) Overview On December 31, 2020, Allscripts Healthcare, LLC, a North Carolina limited liability company (“Allscripts Healthcare”) and subsidiary of Allscripts Healthcare Solutions, Inc., a Delaware corporation (the “Company”), completed the previous

Allscripts Announces $200 Million Accelerated Share Repurchase

Exhibit 99.1 Allscripts Announces $200 Million Accelerated Share Repurchase CHICAGO – December 1, 2020 – Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced that as part of its capital return program it has entered into accelerated share repurchase (“ASR”) transactions with each of JPMorgan Chase Bank, National Association and Wells Fargo Bank, National Association to repurchase an aggr

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2020 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdiction of Incorporat

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35547 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name o

Financial Tables Follow ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2020

Exhibit 99.1 Allscripts Healthcare Solutions, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) Overview On October 15, 2020, Allscripts Healthcare Solutions, Inc. (the “Company”), Allscripts Healthcare, LLC and Allscripts Software, LLC, (collectively, the “EPSi Sellers”) completed the previously-announced divestiture of the EPSi Sellers’ bu

Financial Statements and Exhibits - 8-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2020 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-35547 36-4392754 (State or Other Jurisdi

Allscripts Announces Third Quarter 2020 Results

Exhibit 99.1 Allscripts Announces Third Quarter 2020 Results Third quarter operating margin and Adjusted EBITDA margin increased both year-over-year and sequentially GAAP EPS of $0.00; 18% year-over-year growth in non-GAAP diluted EPS to $0.20 Generated $53 million of operating cash flow and $27 million of free cash flow in the third quarter CHICAGO-(BUSINESS WIRE)-October 29, 2020-Allscripts Heal

Financial Statements and Exhibits, Results of Operations and Financial Condition - ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2020 ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.